Free Trial

Alpha Tau Medical (DRTS) 10K Form and Latest SEC Filings 2026

Alpha Tau Medical logo
$10.41 +0.77 (+7.99%)
Closing price 04:00 PM Eastern
Extended Trading
$10.31 -0.10 (-0.96%)
As of 06:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Latest Alpha Tau Medical SEC Filings & Recent Activity

Alpha Tau Medical (NASDAQ:DRTS) has submitted 131+ documents to the U.S. Securities and Exchange Commission (SEC) since 2021. For investors, these filings are the primary source of verified financial data — covering everything from annual revenue and debt levels in the 10-K, to material business events in 8-K current reports, to insider buying and selling activity in Form 4 disclosures. Key figures from these filings, including revenue, earnings, and cash flow, are summarized in Alpha Tau Medical's financial statements. The most recent filing was a Form 6-K submitted on May 11, 2026.

DateFilerForm TypeView
05/11/2026 8:29 AM
Alpha Tau Medical (1871321) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
05/11/2026 6:00 AM
Alpha Tau Medical (1871321) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
05/08/2026 8:10 AM
Alpha Tau Medical (1871321) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
05/08/2026 8:00 AM
Alpha Tau Medical (1871321) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
05/07/2026 8:00 AM
Alpha Tau Medical (1871321) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
05/05/2026 8:02 AM
Alpha Tau Medical (1871321) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
05/04/2026 8:00 AM
Alpha Tau Medical (1871321) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
05/03/2026 11:15 PM
Alpha Tau Medical (1871321) Filer
Form EFFECT
04/27/2026 6:59 PM
Alpha Tau Medical (1871321) Filer
Form F-3
Registration statement for securities of certain foreign private issuers  
04/27/2026 8:00 AM
Alpha Tau Medical (1871321) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
04/23/2026 8:02 AM
Alpha Tau Medical (1871321) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
03/31/2026 8:15 AM
Alpha Tau Medical (1871321) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
03/18/2026 5:58 PM
Alpha Tau Medical (1871321) Issuer
Levy Raphi (1968095) Reporting
Form 3
Initial statement of beneficial ownership of securities  
03/18/2026 5:59 PM
Alpha Tau Medical (1871321) Issuer
Netser Maya (2043002) Reporting
Form 3
Initial statement of beneficial ownership of securities  
03/18/2026 6:00 PM
Alon Ruth (1796386) Reporting
Alpha Tau Medical (1871321) Issuer
Form 3
Initial statement of beneficial ownership of securities  
03/18/2026 6:01 PM
Alpha Tau Medical (1871321) Issuer
MILCH DAVID MARK (1233803) Reporting
Form 3
Initial statement of beneficial ownership of securities  
03/18/2026 6:02 PM
Alpha Tau Medical (1871321) Issuer
Blumenfeld S Morry (1424202) Reporting
Form 3
Initial statement of beneficial ownership of securities  
03/18/2026 6:03 PM
Adler Alan (1968054) Reporting
Alpha Tau Medical (1871321) Issuer
Form 3
Initial statement of beneficial ownership of securities  
03/18/2026 6:03 PM
Alpha Tau Medical (1871321) Issuer
Sofer Uzi (1968053) Reporting
Form 3
Initial statement of beneficial ownership of securities  
03/18/2026 6:04 PM
Alpha Tau Medical (1871321) Issuer
KIDRON NADAV (1351779) Reporting
Form 3
Initial statement of beneficial ownership of securities  
03/18/2026 6:04 PM
Alpha Tau Medical (1871321) Issuer
Avruch Michael (1968047) Reporting
Form 3
Initial statement of beneficial ownership of securities  
02/26/2026 6:28 AM
Alpha Tau Medical (1871321) Subject
Levy Raphi (1968095) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
02/24/2026 8:01 AM
Alpha Tau Medical (1871321) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
02/02/2026 7:27 AM
Alpha Tau Medical (1871321) Subject
Gat Amnon (1968258) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
01/29/2026 8:00 AM
Alpha Tau Medical (1871321) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
01/14/2026 6:52 AM
Alpha Tau Medical (1871321) Subject
Levy Raphi (1968095) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
01/12/2026 6:35 AM
Alpha Tau Medical (1871321) Subject
Levy Raphi (1968095) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
01/09/2026 5:34 AM
Alpha Tau Medical (1871321) Subject
Gat Amnon (1968258) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
01/09/2026 5:06 AM
Alpha Tau Medical (1871321) Subject
Levy Raphi (1968095) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
01/06/2026 8:02 AM
Alpha Tau Medical (1871321) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
01/05/2026 8:02 AM
Alpha Tau Medical (1871321) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
12/18/2025 8:02 AM
Alpha Tau Medical (1871321) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
12/11/2025 6:03 AM
Alpha Tau Medical (1871321) Subject
Gat Amnon (1968258) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
12/09/2025 8:02 AM
Alpha Tau Medical (1871321) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
12/04/2025 8:02 AM
Alpha Tau Medical (1871321) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
12/02/2025 8:02 AM
Alpha Tau Medical (1871321) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
12/01/2025 5:48 AM
Alpha Tau Medical (1871321) Subject
Gat Amnon (1968258) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
11/20/2025 3:07 PM
Alpha Tau Medical (1871321) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
11/03/2025 5:32 AM
Alpha Tau Medical (1871321) Subject
Gat Amnon (1968258) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
10/21/2025 7:35 AM
Alpha Tau Medical (1871321) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
10/01/2025 6:54 AM
Alpha Tau Medical (1871321) Subject
Gat Amnon (1968258) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
Read this warning immediately (Ad)

Porter Stansberry, founder of one of the world's largest financial research firms, says he's breaking the biggest story of his 26-year career. A famous historian whose books have sold over 45 million copies in 65 languages is warning of a structural shift so large it has only one historical parallel - 1776. One Stanford economist calls it 'the biggest change ever - bigger than electricity, bigger than the steam engine.' Stansberry outlines the stocks to buy, the stocks to sell, and three money moves to position yourself on the right side of this shift.tc pixel

Read Porter Stansberry's full breakdown and protect your wealth now
09/02/2025 7:30 AM
Alpha Tau Medical (1871321) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
08/27/2025 7:32 AM
Alpha Tau Medical (1871321) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
07/24/2025 3:30 PM
Alpha Tau Medical (1871321) Subject
Sofer Uzi (1968053) Filed by
Form SCHEDULE 13G
07/02/2025 11:15 PM
Alpha Tau Medical (1871321) Filer
Form EFFECT
05/28/2025 7:32 AM
Alpha Tau Medical (1871321) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
(Data available from 1/1/2016 forward)

Alpha Tau Medical SEC Filings - Frequently Asked Questions

Alpha Tau Medical (DRTS) has submitted 131+ filings to the SEC since 2021. You can browse the complete history or filter by form type using the tools above.

Alpha Tau Medical's fiscal year ends on December 31. The company typically files its 10-K annual report by the end of February, covering the prior fiscal year's financial results. Key financial data from these reports is available on Alpha Tau Medical's financial statements page.

The most recent filing was a Form 6-K submitted on May 11, 2026. View the full filing using the link above.

SEC Filing Types: 10-K, 10-Q, 8-K and More

SEC filings are legally required disclosures that public companies submit to the U.S. Securities and Exchange Commission. Unlike press releases or earnings call transcripts, these documents are filed under legal obligation — meaning the financial data they contain is audited, standardized, and subject to penalties if materially false. For investors, that makes SEC filings the most reliable primary source available for evaluating a company's true financial position.

Yes. All SEC filings are publicly available through the SEC's EDGAR database and on financial research platforms like MarketBeat. Companies are required by law to make these disclosures accessible to all investors — meaning retail investors have access to the same source documents as institutional analysts.

A 10-K is an annual report containing audited financial statements and a full review of the company's business — it is the most comprehensive filing a company makes each year. A 10-Q is a shorter, unaudited quarterly update filed three times per year between annual reports. Investors typically use the 10-K for deep fundamental analysis and the 10-Q to track whether the company is on pace with its guidance mid-year.

The most important filing for fundamental investors. Filed once per year, the 10-K contains audited financial statements, revenue and earnings trends, debt obligations, risk factors, and management's own assessment of the business. Reading the risk factors section and comparing year-over-year financials can reveal issues that don't show up in analyst summaries.

An unaudited financial update filed three times per year (the 10-K covers Q4). Investors use 10-Qs to track whether guidance is on pace, monitor changes in cash flow or inventory, and catch any mid-year shifts in business conditions before they become headline news.

Filed within four business days of a material event — earnings releases, merger announcements, executive departures, or major asset sales. Because 8-Ks are filed before media coverage catches up, they are often the fastest way to get unfiltered information directly from the company on market-moving events.

Filed within two business days whenever an executive or director buys or sells company stock. Insider purchases — especially large or clustered buys — are often interpreted as a signal of management confidence. Insider selling is more ambiguous but worth monitoring for patterns, particularly around lock-up expirations or ahead of major announcements.


Related Companies and Tools


This page (NASDAQ:DRTS) was last updated on 5/14/2026 by MarketBeat.com Staff.
From Our Partners